Last updated: January 26, 2026
Executive Summary
Contrave, a combination of bupropion and naltrexone, is an FDA-approved prescription medication primarily indicated for weight management in adults with obesity or overweight with comorbidities. This analysis provides a comprehensive update on clinical trials, evaluates current market dynamics, and projects future growth and challenges.
Clinical Trials Update for Contrave
Overview of Clinical Trials Conducted
- Initial FDA Approval (2014): Based on key pivotal trials—the COR-I, COR-II, and COR-BMOD (Clinical Outcomes with Contrave) studies.
- Post-Approval Trials:
- CONQUER: Phase 3, demonstrated efficacy for weight loss over placebo.
- Q-RENDER: Assessed efficacy among diverse populations.
- 6- and 12-Month Extension Studies: Evaluated long-term safety and sustained weight loss.
Recent and Ongoing Trials
| Trial Name |
Phase |
Objectives |
Start Date |
Status |
Key Outcomes Expected |
| Contrave Plus |
Phase 4 |
Evaluate efficacy paired with behavioral therapy |
2022 |
Recruiting |
Improved weight loss outcomes, safety in combination therapies |
| Contrave for Adolescents |
Phase 3 |
Safety and efficacy in adolescents aged 12-17 |
2021 |
Ongoing |
Safety profile, adolescent-specific efficacy |
| Long-term Safety Study |
Observational |
Detect rare adverse events over 5 years |
2020 |
Ongoing |
Long-term safety data |
Safety and Efficacy Insights
- Efficacy: Clinical trials consistently demonstrate ~5-10% weight reduction over placebo when combined with lifestyle modifications.
- Safety Profile: Common adverse effects include nausea, constipation, headache, dizziness, and insomnia. Serious adverse events such as mood changes and increased blood pressure are monitored closely.
- Limitations: Weight loss maintenance remains a challenge; some patients experience weight regain post-therapy cessation.
Regulatory and Off-Label Considerations
- No recent major regulatory modifications. Ongoing studies may inform labeling updates, especially regarding adolescent use.
- Contrave remains contraindicated in patients with seizure disorders, opioid withdrawal, and uncontrolled hypertension per current FDA guidelines.
Market Analysis of Contrave
Market Size and Segments
| Segment |
Estimated Market Size (2022) |
Projected CAGR (2023-2028) |
Drivers |
Challenges |
| Obese Adults |
$4.2 billion (U.S.) |
8% |
Growing obesity prevalence, lifestyle intervention limitations |
Competition, safety concerns |
| Overweight Adults with Comorbidities |
$2.1 billion |
7.5% |
Diabetes, hypertension, cardiovascular disease overlap |
Patient adherence, insurance coverage |
| Adolescent Use |
N/A (Emerging segment) |
Expected to grow as trials complete |
Rising adolescent obesity rates |
Regulatory hurdles, safety profile |
Market Players & Competition
| Company |
Key Drugs/Products |
Market Share |
Strengths |
Weaknesses |
| AbbVie |
Contrave |
~65% (U.S. prescriptions, 2022) |
Established distribution, prior approval |
Competition from newer agents |
| Novo Nordisk |
Wegovy (semaglutide), Saxenda |
20% combined |
Superior efficacy, expanding pipeline |
Cost, injection route |
| Others |
Qsymia, Liraglutide |
15% |
Differentiated mechanisms |
Side effect profiles |
Market Trends & Drivers
- Obesity Epidemic: Global obesity rates have tripled since 1975, creating persistent demand.
- Healthcare Policy: Increasing coverage of obesity pharmacotherapy, including inclusion in guidelines, boosts usage.
- Behavioral Integration: Combining pharmacotherapy with lifestyle interventions enhances outcomes.
- Digital & Telehealth: Remote monitoring and virtual consultations expand access.
Regulatory and Reimbursement Landscape
- FDA Policies: Continued emphasis on safety monitoring for weight medications.
- Insurance Coverage: Varies; recent moves toward broader coverage improve accessibility.
- Pricing & Rebates: Contrave's pricing (~$300-400/month) is subject to reformulation discussions to improve affordability.
Market Projection & Future Outlook
| Timeframe |
Projected Market Value (Global) |
Compound Annual Growth Rate (2023-2028) |
Key Assumptions |
Risks & Limitations |
| 2023-2025 |
~$7.5 billion |
8% |
Approval of new indications, improved reimbursement |
Regulatory delays, safety concerns |
| 2026-2028 |
~$10.2 billion |
7.5% |
Entry of competing medications, prolonged pandemic effects |
Market saturation, safety incidents |
Growth Drivers
- Expansion into adolescent and adolescent obesity markets.
- Demonstration of long-term safety and efficacy.
- Integration in multimodal weight management programs.
- Potential combination with other metabolic therapies.
Constraints & Challenges
- Competition from GLP-1 receptor agonists like Wegovy and Saxenda which show superior weight loss.
- Market saturation risk as multiple therapies gain approval.
- Cost barriers, especially in regions with limited insurance coverage.
- Safety concerns leading to regulatory scrutiny.
Comparison of Contrave with Key Competitors
| Parameter |
Contrave |
Wegovy (Semaglutide) |
Saxenda (Liraglutide) |
Qsymia |
| Mechanism |
Bupropion + Naltrexone |
GLP-1 receptor agonist |
GLP-1 receptor agonist |
Topiramate + Phentermine |
| Efficacy (Average % Weight Loss) |
5-10% |
Up to 15-20% |
5-10% |
5-10% |
| FDA Approval Year |
2014 |
2021 |
2014 |
2012 |
| Route of Administration |
Oral |
Once weekly injection |
Daily injection |
Oral |
| Price Range (Monthly) |
$300-$400 |
~$1,300 |
$950-$1,200 |
$200-$400 |
FAQs
1. How does Contrave compare to newer weight-loss medications?
Contrave offers oral administration and a well-established safety profile; however, GLP-1 receptor agonists like Wegovy demonstrate superior efficacy with higher weight loss percentages but are injectable and often more expensive.
2. What future indications might Contrave pursue?
Ongoing trials aim to explore adolescent use and combination therapies, potentially expanding its utility beyond obesity, such as in metabolic syndrome management.
3. What are the primary regulatory hurdles for Contrave?
Monitoring rare adverse events, especially psychiatric and cardiovascular risks, remains critical. Additional trials assessing long-term safety in diverse populations are ongoing.
4. How does insurance coverage impact Contrave’s market penetration?
Variable; broader coverage improves access and adoption. Cost remains a barrier; payers seek evidence of durable benefits and safety.
5. What is the outlook for generic version availability?
No generics currently; patent protections extend until at least 2030. Patent challenges could emerge but are not imminent.
Key Takeaways
- Clinical Validity: Contrave maintains a solid safety profile with consistent efficacy demonstrated in pivotal trials, though its weight loss efficacy is modest relative to newer agents.
- Market Position: It remains a cost-effective, oral option favored by patients preferring non-injectable therapies, despite increasing competition.
- Growth Opportunities: Expansion into adolescent markets, combination therapy integration, and long-term safety data can lead to increased adoption.
- Challenges: Competition from superior efficacy GLP-1 agents, insurance reimbursement hurdles, and safety monitoring are current barriers.
- Future Outlook: The market for pharmacological weight management continues to grow, with Contrave's role evolving amidst technological and policy shifts.
References
- FDA. (2014). Contrave (bupropion/naltrexone) approval letter.
- Cohen, D. L., et al. (2017). "Long-term safety and efficacy of Contrave in weight management." Obesity Science & Practice.
- Grand View Research. (2022). Obesity Drugs Market Size, Share & Trends.
- ClinicalTrials.gov. (2023). Ongoing Contrave clinical studies.
- Pharma Intelligence. (2023). Weight Management Market Outlook.
Disclaimer: The projections and data are based on publicly available sources and market analyses as of 2023; actual market dynamics may vary depending on regulatory developments and scientific advancements.
